Holen Sie sich die Stockscreener-App
761.45
0.73%
5.55
Handel nachbörslich:
757.11
-4.34
-0.57%
Schlusskurs vom Vortag:
$755.90
Offen:
$759.05
24-Stunden-Volumen:
1.53M
Relative Volume:
1.40
Marktkapitalisierung:
$78.64B
Einnahmen:
$14.25B
Nettoeinkommen (Verlust:
$4.58B
KGV:
18.23
EPS:
41.7701
Netto-Cashflow:
$3.88B
1W Leistung:
+8.11%
1M Leistung:
+31.75%
6M Leistung:
+29.42%
1J Leistung:
+3.18%
1-Tages-Spanne:
$756.64
$773.13
1-Wochen-Bereich:
$699.22
$773.13
52-Wochen-Spanne:
$476.49
$800.99
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Firmenname
Regeneron Pharmaceuticals Inc
Sektor
Branche
Telefon
(914) 847-7000
Adresse
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Vergleichen Sie REGN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
761.45 | 79.44B | 14.25B | 4.58B | 3.88B | 41.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.00 | 108.28B | 11.74B | 3.68B | 3.34B | 14.19 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.23 | 57.65B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
906.74 | 56.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
206.93 | 42.39B | 447.02M | -1.18B | -906.14M | -6.1812 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Perform |
| 2025-08-14 | Eingeleitet | Rothschild & Co Redburn | Buy |
| 2025-06-30 | Herabstufung | Argus | Buy → Hold |
| 2025-05-30 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-05-30 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-02-05 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | Herabstufung | UBS | Buy → Neutral |
| 2024-12-10 | Fortgesetzt | BofA Securities | Underperform |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-14 | Eingeleitet | Citigroup | Neutral |
| 2024-09-24 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | Eingeleitet | Bernstein | Outperform |
| 2024-01-12 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-11-03 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | Bestätigt | Oppenheimer | Perform |
| 2023-06-28 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | Hochstufung | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | Hochstufung | Jefferies | Hold → Buy |
| 2023-03-23 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | Hochstufung | Cowen | Market Perform → Outperform |
| 2023-01-20 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-10-26 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-09-09 | Hochstufung | Jefferies | Underperform → Hold |
| 2022-09-09 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-06-06 | Eingeleitet | Jefferies | Underperform |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2022-01-05 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-01-03 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Overweight |
| 2021-12-07 | Fortgesetzt | Cowen | Market Perform |
| 2021-12-06 | Eingeleitet | Goldman | Buy |
| 2021-11-19 | Fortgesetzt | BMO Capital Markets | Outperform |
| 2021-11-05 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2021-06-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-01-25 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2021-01-08 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-10-05 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2020-07-09 | Hochstufung | SunTrust | Hold → Buy |
| 2020-05-26 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-04-17 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2020-04-08 | Eingeleitet | The Benchmark Company | Hold |
| 2020-03-31 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2020-02-26 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | Hochstufung | Jefferies | Hold → Buy |
| 2020-02-11 | Hochstufung | Argus | Hold → Buy |
| 2019-12-24 | Eingeleitet | Raymond James | Mkt Perform |
| 2019-12-16 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-12-13 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | Eingeleitet | SunTrust | Hold |
| 2019-11-07 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-09-23 | Hochstufung | Guggenheim | Neutral → Buy |
Alle ansehen
Regeneron Pharmaceuticals Inc Aktie (REGN) Neueste Nachrichten
FDA approves new EYLEA HD indication, expanded dosing intervals - Eyes On Eyecare
Truist Securities Lowers Price Target for Regeneron Pharmaceuticals (REGN) to $798 | REGN Stock News - GuruFocus
HSBC Initiates Buy Rating on Regeneron (REGN) with $890 Target - GuruFocus
Regeneron a new buy at HSBC on Eylea HD uptake, cancer therapy catalysts (REGN:NASDAQ) - Seeking Alpha
Scotiabank Raises Price Target for Regeneron Pharmaceuticals (RE - GuruFocus
1 Reason Why Shares of Regeneron Pharmaceuticals Are Surging This Month - Yahoo Finance
Mufg Securities Americas Inc. Has $1.21 Million Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Truist Securities assumes coverage on Regeneron stock with Buy rating - Investing.com
HSBC Initiates Coverage on Regeneron Pharmaceuticals (REGN) with a 'Buy' Rating | REGN Stock News - GuruFocus
HSBC Initiates Regeneron Pharmaceuticals at Buy With $890 Price Target - MarketScreener
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Ensign Peak Advisors Inc - MarketBeat
Jim Cramer Says He "Should Have Been Recommending Regeneron" - Finviz
Jim Cramer Says He “Should Have Been Recommending Regeneron” - Insider Monkey
Tableaux LLC Takes $67.73 Million Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Swiss National Bank Boosts Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
TD Waterhouse Canada Inc. Raises Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Legal & General Group Plc Sells 7,452 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Handelsbanken Fonder AB Boosts Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN is CenterBook Partners LP's 9th Largest Position - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by DNB Asset Management AS - MarketBeat
Empowered Funds LLC Acquires 7,207 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
A Fresh Look at Regeneron Pharmaceuticals (REGN) Valuation After FDA Approval Expands Eylea HD’s Market Potential - simplywall.st
Jim Cramer Answered Questions About These 7 Stocks - Insider Monkey
Franklin Resources Inc. Boosts Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Are Shares of Regeneron Attractive After Recent Surge on Clinical Trial Success? - Yahoo Finance
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Entropy Technologies LP - MarketBeat
ABN AMRO Bank N.V. Purchases New Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Mettler-Toledo, Agilent, Waters Corporation, Merck, and Regeneron Shares Skyrocket, What You Need To Know - Yahoo Finance
Regeneron Pharmaceuticals (NASDAQ:REGN) Trading 4.6% Higher on Analyst Upgrade - MarketBeat
UC Berkeley dean’s research inspires emerging treatment for rare bone disease - University of California, Berkeley
Wells Fargo & Company Boosts Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $700.00 - MarketBeat
Regeneron's EYLEA HD injection 8 mg approved by FDA for the treatment of macular edema following RVO - Ophthalmology Times
Wealthspire Advisors LLC Sells 3,213 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Are Wall Street Analysts Bullish on Regeneron Pharmaceuticals Stock? - Barchart.com
Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by Vanguard Group Inc. - MarketBeat
Sinusitis Drugs Market Generated Opportunities, Future Scope - openPR.com
Creative Planning Has $4.98 Million Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
How Regeneron Pharmaceuticals Inc. (RGO) stock responds to job market shifts2025 Institutional Moves & Growth Focused Entry Point Reports - newser.com
Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MSN
Regeneron Stock: Latest Approvals and Market Shifts - StocksToTrade
Expanded FDA Approvals and Pipeline Wins Could Be a Game Changer For Regeneron Pharmaceuticals (REGN) - simplywall.st
FDA Approves Aflibercept Injection for Macular Edema Following Retinal Vein Occlusion - Drug Topics
Dir Bassler Files To Sell 760 Of Regeneron Pharmaceuticals Inc [REGN] - TradingView
New Approvals Propel Regeneron Stock - timothysykes.com
Novartis, Moderna detail manufacturing expansions in the US, among others - Endpoints News
Regeneron wins 2 Eylea nods, ramping up competition with Roche - Fierce Pharma
Regeneron Wins FDA Nod For Eylea HD With Reduced Injection Schedule For Patients With Vision Loss - Benzinga
With new approvals, Regeneron’s higher-dose Eylea gets more competitive - BioPharma Dive
Wells Fargo Raises Price Target for REGN to $700 | REGN Stock News - GuruFocus
REGN Gets EC Nod for Libtayo Label Expansion, FDA Clears Monthly Eylea HD - Yahoo Finance
EC approval for Libtayo as adjuvant treatment of high-risk CSCC - The Pharma Letter
Finanzdaten der Regeneron Pharmaceuticals Inc-Aktie (REGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.49%
4.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):